Owkin Spinout Waiv Raises $33M to Scale AI‑powered Medical Testing

Why It Matters

The capital infusion enables Waiv to scale AI‑powered oncology tests, potentially setting a new standard for cancer screening worldwide. Its success could accelerate adoption of data‑driven precision medicine across healthcare systems.

Key Takeaways

• Waiv raised $33M led by OTB Ventures.
• AI platform targets precise cancer diagnostics.
• Funding to expand test portfolio and global reach.
• Partnerships with pharma, research institutions, health providers.
• Spinout leverages Owkin's AI expertise for oncology.

Pulse Analysis

The $33 million injection into Waiv marks a pivotal moment for AI‑driven oncology diagnostics in Europe. Emerging from Owkin, a French biotech that has already secured more than $300 million, Waiv inherits a mature machine‑learning pipeline that has been validated across drug‑discovery and clinical research. By isolating the diagnostics arm as a dedicated venture, the founders aim to accelerate product development cycles and attract specialized investors focused on health‑tech innovation. The round also attracted strategic investors such as Serene Data Ventures and Karista, underscoring confidence in Waiv’s data‑centric approach.

Precision medicine hinges on reliable biomarker assays, yet many oncology tests suffer from limited sensitivity and slow turnaround. Waiv’s AI platform promises to integrate genomic, imaging and pathology data, delivering higher accuracy while reducing the need for invasive procedures. The fresh capital will fund new test pipelines, deepen collaborations with pharmaceutical giants, and expand into North American and Asian markets, where demand for scalable, data‑rich diagnostics is surging. Beyond pharma, the platform is being piloted with academic hospitals to generate real‑world evidence, a critical step toward widespread reimbursement.

Regulators are increasingly receptive to AI‑enabled diagnostics, provided they meet stringent validation standards. Waiv’s lineage from Owkin gives it a head start in navigating European Medical Device regulations and securing CE marking, while its global partnership strategy positions it to meet FDA requirements for U.S. roll‑out. Moreover, the company plans to launch a subscription model for continuous test updates, aligning revenue with long‑term clinical outcomes. If the company can translate its algorithmic advances into reimbursable clinical tests, it could reshape oncology screening pathways and set a new benchmark for AI adoption in healthcare.

Deal Summary

Paris‑based healthtech startup Waiv, spun out from Owkin, announced a $33 million funding round co‑led by OTB Ventures and Alpha Intelligence Capital, with participation from Serene Data Ventures, Karista and SistaFund. The capital will be used to expand its AI‑enabled cancer testing platform, build a portfolio of clinical tests and enter new international markets.